Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis

Aim: Iron deficiency (ID) is associated with heart failure (HF) in a considerable proportion of patients. To improve the quality of life, lower the frequency of hospitalizations, and lower mortality rates of chronic HF patients (HF), this meta-analysis will look into the role of iron supplementation...

Full description

Bibliographic Details
Published in:Future Science OA
Main Authors: Burhanuddin Sohail Rangwala, Varisha Zuhair, Muhammad Saqlain Mustafa, Abdullah Mussarat, Aimen Waqar Khan, Fnu Danish, Syeda Mahrukh Fatima Zaidi, Faizan ur Rehman, Muhammad Ashir Shafique
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Subjects:
ferric carboxymaltose
heart failure
iron deficiency
IV iron
LVEF
Online Access:https://www.tandfonline.com/doi/10.1080/20565623.2024.2367956
Description
Summary:Aim: Iron deficiency (ID) is associated with heart failure (HF) in a considerable proportion of patients. To improve the quality of life, lower the frequency of hospitalizations, and lower mortality rates of chronic HF patients (HF), this meta-analysis will look into the role of iron supplementation using ferric carboxymaltose (FCM). Methods & results: From inception until 1 October 2023, we conducted a thorough literature search of electronic databases for peer-reviewed publications. Around 5229 HF patients were included, of which 2691 received FCM while 2538 received placebo. Conclusion: FCM reduces HF-related hospitalizations but doesn't improve overall or cardiovascular mortality in those with HF and ID. The overall results support FCM's role in managing iron deficiency in heart failure.
ISSN:2056-5623

Similar Items